Search results
Results from the WOW.Com Content Network
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1] Sustained-release dosage forms are dosage ...
In other sustained release formulations the matrix swells to form a gel through which the drug exits. Another method by which sustained release is achieved is through an osmotic controlled-release oral delivery system, where the active compound is encased in a water-permeable membrane with a laser drilled hole at one end. As water passes ...
Example of cosmetic gels. Topical gels are commonly used as sustained release dosage forms. [5] [9] Usage of the sustained release dosage form reduces the administration of recurrent doses while maintaining serum dose levels at the therapeutic range (difference between toxic and therapeutic doses), hence improving patient compliance. [5]
Drug delivery systems have been around for many years, but there are a few recent applications of drug delivery that warrant 1. Drug delivery to the brain: Many drugs can be harmful when administered systemically; the brain is very sensitive to medications and can easily cause damage if a drug is administered directly into the bloodstream.
Announcements and reports of future meetings pertaining to the activities of the Controlled Release Society are also included. According to the Journal Citation Reports, the journal has a 2022 impact factor of 10.8, ranking it 10th out of 275 in the category Pharmacology & Pharmacy. [1]
Physical properties of the drug (hydrophobicity, pKa, solubility) The drug formulation (immediate release, excipients used, manufacturing methods, modified release – delayed release, extended release, sustained release, etc.) Whether the formulation is administered in a fed or fasted state; Gastric emptying rate; Circadian differences
In September 2014, a sustained release formulation of the drug was approved for marketing in the United States under the brand name Contrave. [8] [9] The combination was subsequently approved in the European Union in the spring of 2015, where it is sold under the name Mysimba. [5] [10] It was approved in Canada under the Contrave brand name in ...
It can be directed to the location of cancer cells with sustained release behavior. Studies have also been done on gold nanoparticle responses to local near-infrared (NIR) light as a stimuli for drug release. In one study, gold nanoparticles functionalized with double-stranded DNA encapsulated with drug molecules, were irradiated with NIR light.